HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Different altered stage correlative expression of high abundance acute-phase proteins in sera of patients with epithelial ovarian carcinoma.

AbstractBACKGROUND:
The general enhanced expression of alpha1-antichymotrypsin (ACT), clusterin (CLU), alpha1-antitrypsin (AAT), haptoglobin beta-chain (HAP), and leucine rich glycoprotein (LRG) in the sera of patients with epithelial ovarian carcinoma (EOCa) was recently reported. In the present study, we compared the expression of the serum acute-phase proteins (APPs) in the patients according to their stages of cancer.
RESULTS:
Different altered stage correlative expression of the high abundance serum APPs was demonstrated in sera of the patients studied. While the expression of ACT, HAP and AAT appeared to demonstrate positive correlation with the three initial stages of the cancer, inverse correlation was apparently detected in the expression of LRG and CLU. For patients who were diagnosed with stage IV of the cancer, expression of the serum APPs did not conform to the altered progression changes.
CONCLUSION:
Our results highlight the potential prognostic significance of selective high abundance serum APPs in patients with EOCa.
AuthorsYeng Chen, Boon-Kiong Lim, Onn H Hashim
JournalJournal of hematology & oncology (J Hematol Oncol) Vol. 2 Pg. 37 (Aug 27 2009) ISSN: 1756-8722 [Electronic] England
PMID19709441 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Acute-Phase Proteins
Topics
  • Acute-Phase Proteins (analysis, metabolism)
  • Adult
  • Aged
  • Carcinoma in Situ (blood, diagnosis, metabolism, pathology)
  • Case-Control Studies
  • Electrophoresis, Gel, Two-Dimensional
  • Female
  • Humans
  • Metabolome
  • Middle Aged
  • Neoplasm Staging
  • Osmolar Concentration
  • Ovarian Neoplasms (blood, diagnosis, metabolism, pathology)
  • Prognosis
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: